PURE Bioscience Files Patent for Additional Silver Dihydrogen Citrate Formulations.

SAN DIEGO -- Utility Patent Application Covers Silver Dihydrogen Citrate Combined with Traditional Compounds

PURE Bioscience (OTCBB:PURE) today announced it has filed a utility patent application to protect its proprietary silver dihydrogen citrate disinfectant in combination with other antimicrobial compounds, including quaternary ammonia, oxidizers or halogens such as chlorine, bromine or iodine.

PURE's silver dihydrogen citrate (SDC) antimicrobial can serve as a stand-alone, ready-to-use disinfectant product or as an additive to other products. These new SDC inventions, including formulations and methods of use, are a result of PURE's aggressive research and development program to maximize its patented ionic silver antimicrobial technologies.

PURE has already obtained two U.S. patents related to the SDC technology: U.S. Patent 6,197,814 for the original SDC disinfectant and method of its making, and Patent 6,583,176 covering the SDC aqueous disinfectant in combination with ethyl alcohol.

In addition, PURE has received patents in Australia and New Zealand as well as in the EAPC (Eurasian Patent Community) and the OAPI (Organisation Africaine de la Propriete Intellectuelle). Patent applications are pending in Brazil, Canada, China, Japan, Mexico, the EPO (European Patent Office) and the ARIPO (African Regional Industrial Property Organization). These foreign patent applications were filed through the Patent Cooperation Treaty and were published by the World Intellectual Property Organization (www.wipo.org) as Number WO 99/18790 on April 22, 1999.

PURE's innovative molecule, silver dihydrogen citrate (SDC), is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. SDC liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. SDC-based antimicrobial technology is distinguished from competitors in the marketplace because of its superior efficacy combined with reduced toxicity. Silver dihydrogen citrate was invented by Andrew B. Arata, Director of Research and Development for PURE's Bioscience Division.

PURE currently has Environmental Protection Agency (EPA) registration for its 2400-parts per million (ppm) technical grade SDC concentrate (trade name Axenohl(R)) as well as for its Axen(R) and Axen(R)30 hard surface disinfectant products for commercial, industrial and consumer applications including restaurants, homes and medical facilities. In addition to EPA approved uses of SDC technology, PURE, in conjunction with Therapeutics, Incorporated, is pursuing the development and commercialization of Food and Drug Administration (FDA) regulated SDC-based healthcare products.

About PURE Bioscience

PURE Bioscience (PURE) develops and markets technology-based products in the bioscience and water treatment sectors to provide non-toxic solutions to global health challenges. PURE's proprietary high efficacy/low toxicity bioscience platform technologies, including its silver dihydrogen citrate antimicrobials and Triglycylboride(TM) pesticides, represent innovative advances in diverse markets. PURE is currently America's leader in pharmaceutical water purification with its Fillmaster(R) equipment, and the Company has expanded into residential water treatment with its Nutripure(R) water filtration systems. PURE Bioscience is headquartered in El Cajon, California (San Diego metropolitan area) and its common stock trades on the OTC Bulletin Board under the symbol "PURE." Incorporated in 1992, PURE Bioscience was formerly named Innovative Medical Services.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For additional information on PURE Bioscience contact Donna Singer, Executive Vice President, at 619-596-8600 or via email at [e-mail]. On the Web: www.pure-bioscience.com.